Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS® for Signs and Symptoms of Dry Eye Disease

STRIDE 3 was the third Phase 3 clinical trial evaluating EYSUVIS in Dry Eye Disease patients with three separate dose regimens. The study was randomized, double-masked, placebo-controlled, multicenter trial comparing EYSUVIS to saline placebo treatment. A total of 657 patients were randomized 2:1 to receive EYSUVIS or saline placebo respectively. The primary endpoint was improvement in both the dry eye disease symptom score and the ocular surface disease index (OSDI). The secondary endpoints included improvements in the dry eye disease symptom score and the ocular surface disease index (OSDI), the patient’s visual analog scale (VAS) for dry eye symptoms, and the patient’s quality of life (QOL) on a questionnaire.

The results demonstrate statistical significance for both the primary and secondary endpoints. This is the first time ever that a topical treatment has been shown to be statistically significant in improving the symptoms and ocular surface disease in dry eye disease patients. The results were consistent across all dose regimens and were statistically significant at the level of p<0.001. The study was sponsored by Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals, Inc. (Kala/Nasdaq: KALA) is a pharmaceutical company focused on the discovery, development and commercialization of innovative therapies for the treatment of diseases of the eye, facial mucous membranes and the skin.

Kala Pharmaceuticals, Inc.

900 Meade Street
Redwood City, CA 94063

Telephone: 855-996-KALA
www.kala.com

E-mail: info@kala.com

Issued: 2023-02-03, 1:00 PM ET

Contact:
Kala Pharmaceuticals, Inc.

900 Meade Street
Redwood City, CA 94063

Telephone: 855-996-KALA
www.kala.com

E-mail: info@kala.com

Issued: 2023-02-03, 1:00 PM ET

Media:
Siddhartha Gore-Leese

Siddhartha Gore-Leese

508-600-8803

Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS® for Signs and Symptoms of Dry Eye Disease

The statistically significant improvement in the primary endpoint of dry eye disease symptom score (p<0.001) was observed across all dose regimens and was maintained through the final follow-up visit. The improvement was also statistically significant for the secondary endpoints of ocular surface disease index and visual analog scale for dry eye symptoms. The results demonstrate that EYSUVIS is effective in the treatment of dry eye disease and provides relief from the symptoms and signs associated with the disease.

The study was designed to evaluate the safety and efficacy of EYSUVIS in the treatment of dry eye disease in a randomized, double-masked, placebo-controlled, multicenter trial. The primary endpoint was improvement in the dry eye disease symptom score, as measured by the Ocular Surface Disease Index (OSDI), and the patient’s visual analog scale (VAS) for dry eye symptoms.

The results of the STRIDE 3 study demonstrate that EYSUVIS is effective in the treatment of dry eye disease and provides relief from the symptoms and signs associated with the disease. The study was designed to evaluate the safety and efficacy of EYSUVIS in the treatment of dry eye disease in a randomized, double-masked, placebo-controlled, multicenter trial. The primary endpoint was improvement in the dry eye disease symptom score, as measured by the Ocular Surface Disease Index (OSDI), and the patient’s visual analog scale (VAS) for dry eye symptoms.

The results of the STRIDE 3 study demonstrate that EYSUVIS is effective in the treatment of dry eye disease and provides relief from the symptoms and signs associated with the disease. The study was designed to evaluate the safety and efficacy of EYSUVIS in the treatment of dry eye disease in a randomized, double-masked, placebo-controlled, multicenter trial. The primary endpoint was improvement in the dry eye disease symptom score, as measured by the Ocular Surface Disease Index (OSDI), and the patient’s visual analog scale (VAS) for dry eye symptoms.

The results of the STRIDE 3 study demonstrate that EYSUVIS is effective in the treatment of dry eye disease and provides relief from the symptoms and signs associated with the disease. The study was designed to evaluate the safety and efficacy of EYSUVIS in the treatment of dry eye disease in a randomized, double-masked, placebo-controlled, multicenter trial. The primary endpoint was improvement in the dry eye disease symptom score, as measured by the Ocular Surface Disease Index (OSDI), and the patient’s visual analog scale (VAS) for dry eye symptoms.

The results of the STRIDE 3 study demonstrate that EYSUVIS is effective in the treatment of dry eye disease and provides relief from the symptoms and signs associated with the disease. The study was designed to evaluate the safety and efficacy of EYSUVIS in the treatment of dry eye disease in a randomized, double-masked, placebo-controlled, multicenter trial. The primary endpoint was improvement in the dry eye disease symptom score, as measured by the Ocular Surface Disease Index (OSDI), and the patient’s visual analog scale (VAS) for dry eye symptoms.

The results of the STRIDE 3 study demonstrate that EYSUVIS is effective in the treatment of dry eye disease and provides relief from the symptoms and signs associated with the disease. The study was designed to evaluate the safety and efficacy of EYSUVIS in the treatment of dry eye disease in a randomized, double-masked, placebo-controlled, multicenter trial. The primary endpoint was improvement in the dry eye disease symptom score, as measured by the Ocular Surface Disease Index (OSDI), and the patient’s visual analog scale (VAS) for dry eye symptoms.

The results of the STRIDE 3 study demonstrate that EYSUVIS is effective in the treatment of dry eye disease and provides relief from the symptoms and signs associated with the disease. The study was designed to evaluate the safety and efficacy of EYSUVIS in the treatment of dry eye disease in a randomized, double-masked, placebo-controlled, multicenter trial. The primary endpoint was improvement in the dry eye disease symptom score, as measured by the Ocular Surface Disease Index (OSDI), and the patient’s visual analog scale (VAS) for dry eye symptoms.

The results of the STRIDE 3 study demonstrate that EYSUVIS is effective in the treatment of dry eye disease and provides relief from the symptoms and signs associated with the disease. The study was designed to evaluate the safety and efficacy of EYSUVIS in the treatment of dry eye disease in a randomized, double-masked, placebo-controlled, multicenter trial. The primary endpoint was improvement in the dry eye disease symptom score, as measured by the Ocular Surface Disease Index (OSDI), and the patient’s visual analog scale (VAS) for dry eye symptoms.

The results of the STRIDE 3 study demonstrate that EYSUVIS is effective in the treatment of dry eye disease and provides relief from the symptoms and signs associated with the disease. The study was designed to evaluate the safety and efficacy of EYSUVIS in the treatment of dry eye disease in a randomized, double-masked, placebo-controlled, multicenter trial. The primary endpoint was improvement in the dry eye disease symptom score, as measured by the Ocular Surface Disease Index (OSDI), and the patient’s visual analog scale (VAS) for dry eye symptoms.